10-Q: Tempus AI Reports Strong Revenue Growth in Q2 2026

Tempus AI, Inc. announced its Q2 2026 financial results, showcasing a significant increase in total net revenue driven by strong performance in both its Diagnostics and Data and applications segments.

Summary

• Tempus AI reported total net revenue of $382.5 million for the three months ended June 30, 2026, a 22% increase compared to $314.6 million in the same period of 2025.
• For the six months ended June 30, 2026, total net revenue reached $730.6 million, up 28% from $570.4 million in the prior year period.
• The company reported a net income of $5.6 million for the three months ended June 30, 2026, a significant improvement from a net loss of $42.8 million in the prior year period.
• However, for the six months ended June 30, 2026, the company incurred a net loss of $120.3 million, compared to a net loss of $110.9 million in the same period of 2025.
• Adjusted EBITDA showed improvement, with $8.0 million for Q2 2026 compared to a loss of $5.6 million in Q2 2025, and $5.2 million for the six months ended June 30, 2026, compared to a loss of $21.8 million in the prior year period.
• The company completed a $460.0 million offering of 0.00% Convertible Senior Notes due 2032.
• The company announced a proposed acquisition of Personalis, Inc. for an enterprise value of $1.5 billion.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth and a return to profitability in the latest quarter, despite ongoing investments and a net loss for the year-to-date period. The proposed acquisition of Personalis is a significant strategic move.

Positives

• Total net revenue increased by 22% to $382.5 million for the three months ended June 30, 2026, compared to the prior year period.
• Diagnostics revenue grew by 20% to $289.3 million, driven by increased volume of oncology and hereditary tests.
• Data and applications revenue increased by 28% to $93.2 million, primarily due to higher demand for Insights products.
• The company achieved net income of $5.6 million for the three months ended June 30, 2026, a substantial turnaround from a net loss in the prior year.
• Adjusted EBITDA improved significantly, turning positive at $8.0 million for the three months ended June 30, 2026, from a loss of $5.6 million in the prior year period.
• Interest income increased by 257% to $3.9 million due to higher cash balances.
• The company repaid its credit facilities in full, reducing future interest expenses.

Negatives

• The company reported a net loss of $120.3 million for the six months ended June 30, 2026, an increase from the prior year period.
• Selling, general and administrative expenses increased by 25% to $225.8 million for the three months ended June 30, 2026.
• Research and development expenses increased by 26% to $52.6 million for the three months ended June 30, 2026.
• Technology research and development expenses increased by 27% to $43.9 million for the three months ended June 30, 2026.
• The company incurred a loss on debt extinguishment of $11.6 million related to the repayment of credit facilities.
• The company has an accumulated deficit of $2.5 billion as of June 30, 2026.

Risks

• The proposed acquisition of Personalis, Inc. may not be completed due to various closing conditions, which could negatively impact the company's stock price and business operations.
• Failure to successfully integrate the businesses and operations of Tempus AI and Personalis could adversely affect the combined company's performance.
• Litigation related to the proposed acquisition could result in injunctions or substantial costs.
• The company's convertible senior notes and the potential issuance of shares upon conversion could lead to dilution and downward pressure on the stock price.
• The company faces counterparty risk with respect to its capped call transactions.
• The company's financial performance relies heavily on securing reimbursement from payers and government health benefits programs.
• The company is subject to ongoing legal proceedings, including patent infringement claims and alleged violations of privacy laws.

Future Outlook

The company expects to maintain high levels of investment in product innovation, technology development, and sales and marketing to drive growth. They anticipate increased capital expenditure requirements if additional laboratory capacity is needed. The company believes its current cash and cash equivalents and marketable equity securities are sufficient to fund its operating plan for at least one year.

Management Comments

• We believe Intelligent Diagnostics represent the future of precision medicine, informing more personalized and data-driven therapy selection and development.
• We believe their adoption could empower physicians to deliver better care and researchers to develop more precise therapies, with the potential to save millions of lives.
• We built both a technology platform to free healthcare data from silos and an operating system to make this data useful, the combination of which we refer to as our Platform.

Industry Context

StockSavvy.ai notes that Tempus AI's focus on AI and machine learning in healthcare aligns with a major industry trend towards data-driven diagnostics and personalized medicine. The company's strategy of integrating laboratory testing with data analytics positions it to capitalize on the growing demand for advanced healthcare solutions.

Legal Proceedings

• Guardant Health Inc. has filed patent infringement lawsuits alleging that Tempus's products infringe five Guardant patents.
• Tempus has filed counterclaims against Guardant alleging false and misleading advertisements.
• Lawsuits have been filed alleging violations of the Illinois Genetic Information Privacy Act and other state privacy laws, seeking class action status.
• The company received a subpoena from the Ohio Attorney General regarding billing and patient records for Ohio Medicaid patients.
• The U.S. Attorneys Office for the Eastern District of New York issued a Civil Investigative Demand related to compliance with the False Claims Act and Anti-Kickback statute.

Related Party Transactions

• The company has a Master Agreement with Pathos AI, Inc., where the CEO is a co-founder and Executive Chairman.
• Pathos AI is developing a foundation large multimodal model in oncology, with Tempus licensing de-identified data to assist.
• Pathos will pay Tempus $200 million over three years for data license fees, with an upfront payment of $50 million already made.
• Tempus paid Pathos $35 million, with $25 million paid to date, in consideration for Pathos' commitments.
• Pathos paid $8.8 million of data license fees in Pathos' Series D Preferred Stock in June 2026.
• The company entered into an Independent Contractor Agreement with Iker Huerga, CEO of Pathos, for consulting services.

Stakeholder Impact

• Shareholders may experience dilution if convertible notes are converted.
• The proposed acquisition of Personalis could lead to significant integration challenges and potential loss of key personnel.
• Customers (physicians, research institutions, pharmaceutical companies) benefit from Tempus's advanced diagnostics and data services.
• Suppliers may be impacted by the company's growth and strategic initiatives.
• Creditors' positions are affected by the company's debt levels and repayment activities.

Next Steps

• Complete the acquisition of Personalis, Inc., subject to shareholder approval and regulatory approvals.
• Continue to invest in product innovation, technology development, and sales and marketing efforts.
• Manage and integrate the combined operations of Tempus AI and Personalis, if the acquisition is completed.
• Monitor and manage legal proceedings, including patent infringement claims and privacy law allegations.

Key Dates

Recommendation

While Tempus AI shows strong revenue growth and improved quarterly profitability, the significant net loss for the year-to-date, ongoing R&D and SG&A investments, and substantial legal risks warrant a cautious approach. The proposed acquisition of Personalis is a major strategic move with integration risks. Therefore, a 'hold' recommendation is appropriate pending further clarity on the acquisition's success and resolution of legal matters.

Keywords

healthcare technology, genomics, AI in healthcare, precision medicine, diagnostics, data licensing, clinical trials, oncology